Shionogi, GSK move HIV drug into PhIII

GlaxoSmithKline (NYSE: GSK) and partner Shionogi say they are bringing their once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 into Phase III trials. According to an announcement, ‘572 will be the only such product so far along in development.  The companies' decision is based on promising results from two Phase IIb trials, SPRING-1 and VIKING, being presented this week at the XVIII International AIDS Conference in Vienna, Austria. If it performs well in tests,...